Title:
過敏症の治療のための免疫賦活性核酸パッケージ粒子
Document Type and Number:
Japanese Patent JP5484732
Kind Code:
B2
Abstract:
The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.
Inventors:
Renner, Wolfgang
Bachmann, Martin
Seelens, Injuris
Koester, Conrad
Deat myer, claus
Fuchs, zebastian
Manorova, Bania
Maurer, Patrick
Pumpens, Paul
Renhofa, Regina
Alan Tissot
Elephant, you
Prova, curl
Kinzler, Machias
Bachmann, Martin
Seelens, Injuris
Koester, Conrad
Deat myer, claus
Fuchs, zebastian
Manorova, Bania
Maurer, Patrick
Pumpens, Paul
Renhofa, Regina
Alan Tissot
Elephant, you
Prova, curl
Kinzler, Machias
Application Number:
JP2008545008A
Publication Date:
May 07, 2014
Filing Date:
December 14, 2006
Export Citation:
Assignee:
Sights Biotechnology AG
International Classes:
A61K31/7088; A61K9/127; A61K9/14; A61K9/50; A61K39/39; A61K47/42; A61P11/06; A61P17/00; A61P37/08
Domestic Patent References:
| JP2005507388A | ||||
| JP2005517632A |
Foreign References:
| WO2005004907A1 | ||||
| WO2004000351A1 | ||||
| US20050101557 |
Other References:
Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice,International Immunopharmacology,2004年,4, 7,p.851-862
Immunomodulatoryeffects of CpG oligodeoxynucleotides onestablished Th2 responses,Clin Diagn Lab Immunol,2002年,9,p.1260-9
Systemic administration of immunostimulatory DNAsequences mediates reversible inhibition of Th2 responses ina mouse model of asthma,J Clin Immunol,2001年,21,p.175-82
Treatment ofestablished asthma in a murine model using CpG oligodeoxynucleotides,Am J Physiol, Lung Cell Mol Physiol,2002年,283,L170-9
Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: twounique but complementary strategies for the treatment of allergicdiseases,J Allergy Clin Immunol,2002年,110,p.706-12
CpG oligodeoxynucleotides can reverse Th2-associated allergicairway responses and alter the B7.1/B7.2 expression in amurine model of asthma.,J Immunol,2000年,165,p.5906-12
Amb a 1-linked CpG oligodeoxynucleotides reverse establishedairway hyperresponsiveness in a murine model of asthma,J Allergy Clin Immunol,2002年,109,p.455-62
CpG oligodeoxynucleotides: a noveltherapeutic approach for atopic disorders,CURRENT DRUG TARGETS - INFLAMMATION & ALLERGY,2003年,2,p.199-205
Immunomodulatoryeffects of CpG oligodeoxynucleotides onestablished Th2 responses,Clin Diagn Lab Immunol,2002年,9,p.1260-9
Systemic administration of immunostimulatory DNAsequences mediates reversible inhibition of Th2 responses ina mouse model of asthma,J Clin Immunol,2001年,21,p.175-82
Treatment ofestablished asthma in a murine model using CpG oligodeoxynucleotides,Am J Physiol, Lung Cell Mol Physiol,2002年,283,L170-9
Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: twounique but complementary strategies for the treatment of allergicdiseases,J Allergy Clin Immunol,2002年,110,p.706-12
CpG oligodeoxynucleotides can reverse Th2-associated allergicairway responses and alter the B7.1/B7.2 expression in amurine model of asthma.,J Immunol,2000年,165,p.5906-12
Amb a 1-linked CpG oligodeoxynucleotides reverse establishedairway hyperresponsiveness in a murine model of asthma,J Allergy Clin Immunol,2002年,109,p.455-62
CpG oligodeoxynucleotides: a noveltherapeutic approach for atopic disorders,CURRENT DRUG TARGETS - INFLAMMATION & ALLERGY,2003年,2,p.199-205
Attorney, Agent or Firm:
Sonoda Yoshitaka
Kobayashi Yoshinori
Kobayashi Yoshinori
Previous Patent: PREPARATION OF MAGNETIC TONER
Next Patent: SELECTING METHOD OF IMAGE SUPPORTING SHEET FEEDER
Next Patent: SELECTING METHOD OF IMAGE SUPPORTING SHEET FEEDER